Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag

Virus Research

Volumn 192, Issue , 2014, Pages 25-33

  Garrod, Tamsin J ^a   Gargett, Tessa ^a   Yu, Wenbo ^a   Major, Lee ^b   Burrell, Christopher J ^a   Wesselingh, Steven ^c   Suhrbier, Andreas ^b   Grubor Bauk, Branka ^a   Gowans, Eric J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

DNA vaccine; EcoHIV challenge; HIV

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; POL PROTEIN; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; SPLEEN CELL; VIRUS INCLUSION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HIV INFECTIONS; IMMUNOLOGY; SPLEEN;

AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIGENS; HIV INFECTIONS; MICE, INBRED C57BL; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SPLEEN; VACCINES;

EID: 84908123713     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.08.008     Document Type: Article

References (40)

1. Akinsiku O.T., Bansal A., Sabbaj S., Heath S.L., Goepfert P.A. Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression. J. Acquir. Immune Defic. Syndr. 2011, 58(2):132-140.
2. Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Villinger F., Altman J.D., O'Neil S.P., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McNicholl J.M., McClure H.M., Moss B., Robinson H.L. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 2002, 76(12):6138-6146.
3. Benlahrech A., Harris J., Meiser A., Papagatsias T., Hornig J., Hayes P., Lieber A., Athanasopoulos T., Bachy V., Csomor E., Daniels R., Fisher K., Gotch F., Seymour L., Logan K., Barbagallo R., Klavinskis L., Dickson G., Patterson S. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(47):19940-19945.
4. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., Lederman M.M., Benito J.M., Goepfert P.A., Connors M., Roederer M., Koup R.A. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(12):4781-4789.
5. Boaz M.J., Waters A., Murad S., Easterbrook P.J., Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J. Immunol. 2002, 169(11):6376-6385.
6. Bolesta E., Gzyl J., Wierzbicki A., Kmieciak D., Kowalczyk A., Kaneko Y., Srinivasan A., Kozbor D. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens. Virology 2005, 332(2):467-479.
7. Brave A., Hinkula J., Cafaro A., Eriksson L.E., Srivastava I.K., Magnani M., Ensoli B., Barnett S.W., Wahren B., Rollman E. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. Vaccine 2007, 25(39-40):6882-6890.
8. Brave A., Ljungberg K., Boberg A., Rollman E., Isaguliants M., Lundgren B., Blomberg P., Hinkula J., Wahren B. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol. Ther. 2005, 12(6):1197-1205.
9. Bridge S.H., Sharpe S.A., Dennis M.J., Dowall S.D., Getty B., Anson D.S., Skinner M.A., Stewart J.P., Blanchard T.J. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles. Virol. J. 2011, 8:429.
10. Carnero E., Li W., Borderia A.V., Moltedo B., Moran T., Garcia-Sastre A. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J. Virol. 2009, 83(2):584-597.
11. Chen S.W., Chiu H.C., Liao W.H., Wang F.D., Chen S.S., Wang C.T. The virus-associated human immunodeficiency virus type 1 Gag-Pol carrying an active protease domain in the matrix region is severely defective both in autoprocessing and in trans processing of gag particles. Virology 2004, 318(2):534-541.
12. Cox J.H., Ferrari G., Kalams S.A., Lopaczynski W., Oden N., D'Souza M.P. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retroviruses 2005, 21(1):68-81.
13. de Oliveira T., Engelbrecht S., Janse van Rensburg E., Gordon M., Bishop K., zur Megede J., Barnett S.W., Cassol S. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?. J. Virol. 2003, 77(17):9422-9430.
14. Deml L., Speth C., Dierich M.P., Wolf H., Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol. Immunol. 2005, 42(2):259-277.
15. Earl P.L., Cotter C., Moss B., VanCott T., Currier J., Eller L.A., McCutchan F., Birx D.L., Michael N.L., Marovich M.A., Robb M., Cox J.H. Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 2009, 27(42):5885-5895.
16. Egan M.A., Megati S., Roopchand V., Garcia-Hand D., Luckay A., Chong S.Y., Rosati M., Sackitey S., Weiner D.B., Felber B.K., Pavlakis G.N., Israel Z.R., Eldridge J.H., Sidhu M.K. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine 2006, 24(21):4510-4523.
17. Frosner G., Steffen R., Herzog C. Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration. J. Travel Med. 2009, 16(6):413-419.
18. Gargett T., Grubor-Bauk B., Garrod T.J., Yu W., Miller D., Major L., Wesselingh S., Suhrbier A., Gowans E.J. Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response. Immunol. Cell Biol. 2013.
19. Garrod T.J., Grubor-Bauk B., Gargett T., Li Y., Miller D.S., Yu W., Major L., Burrell C.J., Wesselingh S., Suhrbier A., Gowans E.J. DNA vaccines encoding membrane-bound or secreted forms of heat shock protein 70 exhibit improved potency. Eur. J. Immunol. 2014.
20. Harrer T., Harrer E., Kalams S.A., Barbosa P., Trocha A., Johnson R.P., Elbeik T., Feinberg M.B., Buchbinder S.P., Walker B.D. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J. Immunol. 1996, 156(7):2616-2623.
21. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., Liao H.X., DeVico A.L., Lewis G.K., Williams C., Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N., Robb M.L., Ngauy V., de Souza M.S., Paris R., Ferrari G., Bailer R.T., Soderberg K.A., Andrews C., Berman P.W., Frahm N., De Rosa S.C., Alpert M.D., Yates N.L., Shen X., Koup R.A., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Michael N.L., Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366(14):1275-1286.
22. Huang Y., Kong W.P., Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 2001, 75(10):4947-4951.
23. Hudgens M.G., Self S.G., Chiu Y.L., Russell N.D., Horton H., McElrath M.J. Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. J. Immunol. Methods 2004, 288(1-2):19-34.
24. Kashi V.P., Jacob R.A., Paul S., Nayak K., Satish B., Swaminathan S., Satish K.S., Ranga U. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently. Vaccine 2009, 27(48):6739-6747.
25. Molder T., Adojaan M., Kaldma K., Ustav M., Sikut R. Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multi-component fusion protein MultiHIV - study in domestic pigs. Vaccine 2009, 28(2):293-298.
26. Mooij P., Nieuwenhuis I.G., Knoop C.J., Doms R.W., Bogers W.M., Ten Haaft P.J., Niphuis H., Koornstra W., Bieler K., Kostler J., Morein B., Cafaro A., Ensoli B., Wagner R., Heeney J.L. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J. Virol. 2004, 78(7):3333-3342.
27. Moormann A.M., Sumba P.O., Chelimo K., Fang H., Tisch D.J., Dent A.E., John C.C., Long C.A., Vulule J., Kazura J.W. Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites. J. Infect. Dis. 2013, 208(1):149-158.
28. Nitayaphan S., Pitisuttithum P., Karnasuta C., Eamsila C., de Souza M., Morgan P., Polonis V., Benenson M., VanCott T., Ratto-Kim S., Kim J., Thapinta D., Garner R., Bussaratid V., Singharaj P., el-Habib R., Gurunathan S., Heyward W., Birx D., McNeil J., Brown A.E. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 2004, 190(4):702-706.
29. Otten G.R., Schaefer M., Doe B., Liu H., Megede J.Z., Donnelly J., Rabussay D., Barnett S., Ulmer J.B. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006, 24(21):4503-4509.
30. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., Walker C.M. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 2000, 16(3):273-282.
31. Potash M.J., Chao W., Bentsman G., Paris N., Saini M., Nitkiewicz J., Belem P., Sharer L., Brooks A.I., Volsky D.J. A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc. Natl. Acad. Sci. U.S.A. 2005, 102(10):3760-3765.
32. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361(23):2209-2220.
33. Riou C., Burgers W.A., Mlisana K., Koup R.A., Roederer M., Abdool Karim S.S., Williamson C., Gray C.M. Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point. J. Virol. 2014, 88(3):1819-1824.
34. Rollman E., Brave A., Boberg A., Gudmundsdotter L., Engstrom G., Isaguliants M., Ljungberg K., Lundgren B., Blomberg P., Hinkula J., Hejdeman B., Sandstrom E., Liu M., Wahren B. The rationale behind a vaccine based on multiple HIV antigens. Microbes Infect. 2005, 7(14):1414-1423.
35. Roshorm Y., Cottingham M.G., Potash M.J., Volsky D.J., Hanke T. T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load. Eur. J. Immunol. 2012, 42(12):3243-3255.
36. Saini M., Hadas E., Volsky D.J., Potash M.J. Vaccine-induced protection from infection of mice by chimeric human immunodeficiency virus type 1, EcoHIV/NL4-3. Vaccine 2007, 25(52):8660-8663.
37. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J. Exp. Med. 2008, 205(1):7-12.
38. Vaccari M., Poonam P., Franchini G. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. Expert Rev. Vaccines 2010, 9(9):997-1005.
39. Young K.R., McBurney S.P., Karkhanis L.U., Ross T.M. Virus-like particles: designing an effective AIDS vaccine. Methods 2006, 40(1):98-117.
40. zur Megede J., Otten G.R., Doe B., Liu H., Leung L., Ulmer J.B., Donnelly J.J., Barnett S.W. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines. J. Virol. 2003, 77(11):6197-6207.